-
公开(公告)号：US20160081337A1
公开(公告)日：2016-03-24
申请号：US14783622
申请日：2014-04-11
Applicant: E. I. DU PONT DE NEMOURS AND COMPANY
Inventor： JAMES FRANCIS BEREZNAK , ANDREW EDMUND TAGGI , MOUMITA KAR , RAVISEKHARA POCHIMIREDD REDDY , MATTHEW JAMES CAMPBELL
IPC: A01N43/60 , A01N43/56 , A01N43/58 , C07D401/14
CPC classification number: A01N43/60 , A01N43/56 , A01N43/58 , C07D215/20 , C07D231/14 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/06 , C07D417/14 , C07D419/10
Abstract: Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein A is a radical selected from the group consisting of A-1 through A-11, L is —C(R12a)R12b—C(R13a)R13b—; or 1,2-phenylene G is a radical selected from the group consisting of and R1, R2, R12a, R12b, R13a, R13b and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
Abstract translation: 公开了式1的化合物，包括所有的立体异构体，N-氧化物及其盐，其中A是选自A-1至A-11的基团，L是-C（R 12a）R 12b-C（R 13a ）R13b-; 或1,2-亚苯基G是选自以下的基团：R 1，R 2，R 12a，R 12b，R 13a，R 13b和Q如本公开所定义。 还公开了含有式1化合物的组合物和用于控制由真菌病原体引起的植物病害的方法，包括施用有效量的本发明化合物或组合物。
-
2.发明申请OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF 有权用苄基或异二甲苯基取代的氧化氮衍生物，其生产方法，用作含有所述衍生物的药物和药物及其用途
公开(公告)号：US20140066437A1
公开(公告)日：2014-03-06
申请号：US14003392
申请日：2012-03-07
Applicant: Thomas Boehme , Christian Engel , Stefan Guessregen , Torsten Haack , Kurt Ritter , Georg Tschank
Inventor： Thomas Boehme , Christian Engel , Stefan Guessregen , Torsten Haack , Kurt Ritter , Georg Tschank
IPC: A61K31/54 , A61K47/06 , C07D419/14 , C07D291/06 , C07D419/10
CPC classification number: A61K31/54 , A61K47/06 , C07D291/06 , C07D419/10 , C07D419/14
Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
Abstract translation: 本发明涉及式（I）化合物及其生理上可接受的盐。 所述化合物是合适的。 用于治疗高血糖症。
-
公开(公告)号：US20110281910A1
公开(公告)日：2011-11-17
申请号：US12942183
申请日：2010-11-09
Applicant: Rico Lavoie , John A. Bender , Jeffrey Lee Romine , Edward H. Ruediger , Carol Bachand , Omar D. Lopez , Qi Chen , Makonen Belema , John F. Kadow , Lawrence G. Hamann
Inventor： Rico Lavoie , John A. Bender , Jeffrey Lee Romine , Edward H. Ruediger , Carol Bachand , Omar D. Lopez , Qi Chen , Makonen Belema , John F. Kadow , Lawrence G. Hamann
IPC: A61K31/4178 , C07D417/14 , C07D413/14 , C07D403/14 , A61P31/14 , C07D407/14 , A61K31/427 , A61K31/422 , A61K31/4545 , C07D409/14 , C07D401/14
CPC classification number: C07D417/14 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10 , C07D419/10 , C07D493/08
Abstract: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
Abstract translation: 本公开涉及式（I）的新化合物或说明书中定义的和包含这些新化合物的组合物。 这些化合物是有用的抗病毒剂，特别是抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能。 因此，本公开还涉及通过使用这些新化合物或包含这些新化合物的组合物治疗HCV相关疾病或病症的方法。
-
公开(公告)号：US20230183214A1
公开(公告)日：2023-06-15
申请号：US17920850
申请日：2021-05-04
Applicant: Brandon D. CASH , Wenlang FU , George Madalin GIAMBASU , Andrew M. HAIDLE , Brett A. HOPKINS , Matthew A. LARSEN , Charles A. LESBURG , Ping LIU , Meredeth A. MCGOWAN , Qinglin PU , Sulagna SANYAL , Phieng SILIPHAIVANH , Catherine M. WHITE , Xin YAN , Merck Sharp & Dohme LLC
Inventor： Brandon D. CASH , Wenlang FU , George Madalin GIAMBASU , Andrew M. HAIDLE , Brett A. HOPKINS , Matthew A. LARSEN , Charles A. LESBURG , Ping LIU , Meredeth A. MCGOWAN , Qinglin PU , Sulagna SANYAL , Phieng SILIPHAIVANH , Catherine M. WHITE , Xin YAN
IPC: C07D403/10 , C07D413/10 , C07D409/06 , C07D235/26 , C07D403/06 , C07D419/10 , C07D401/14 , C07D401/06 , C07D409/14 , C07D405/06 , C07D401/12 , C07D401/08 , C07D495/04 , C07D417/10
CPC classification number: C07D403/10 , C07D235/26 , C07D401/06 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D413/10 , C07D417/10 , C07D419/10 , C07D495/04
Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.
-
公开(公告)号：US20140018389A1
公开(公告)日：2014-01-16
申请号：US14027531
申请日：2013-09-16
Applicant: Bristol-Myers Squibb Company
Inventor： Rico Lavoie , John A. Bender , Jeffrey Lee Romine , Edward H. Ruediger , Carol Bachand , Omar D. Lopez , Qi Chen , Makonen Belema , John F. Kadow , Lawrence G. Hamann
IPC: C07D417/14 , C07D405/14 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14
CPC classification number: C07D417/14 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10 , C07D419/10 , C07D493/08
Abstract: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
Abstract translation: 本公开涉及式（I）的新化合物或说明书中定义的和包含这些新化合物的组合物。 这些化合物是有用的抗病毒剂，特别是抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能。 因此，本公开还涉及通过使用这些新化合物或包含这些新化合物的组合物治疗HCV相关疾病或病症的方法。
-
公开(公告)号：US6100252A
公开(公告)日：2000-08-08
申请号：US207044
申请日：1998-12-08
Applicant: Takehiko Naka , Yoshiyuki Inada
Inventor： Takehiko Naka , Yoshiyuki Inada
IPC: A61K31/415 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/433 , A61K31/435 , A61K31/4365 , A61K31/495 , A61K31/505 , A61K31/513 , A61K31/517 , A61K31/535 , A61P9/00 , A61P9/10 , A61P9/12 , A61P25/28 , A61P43/00 , B29D22/00 , B32B27/42 , C07D285/08 , C07D403/10 , C07D413/10 , C07D417/10 , C07D419/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00
CPC classification number: C07D403/10 , A61K31/42 , A61K31/435 , C07D411/10 , C07D411/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D419/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04 , Y02P20/55
Abstract: ##STR1## Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.
Abstract translation: 上述式表示的化合物或其盐显示出强的血管紧张素II拮抗作用和降血压作用和CNS活性，并且可用作循环系统疾病如高血压疾病和心脏病（例如高血压，心力衰竭，心肌梗塞）的治疗剂， 脑卒中，脑中风，肾炎，动脉粥样硬化，阿尔茨海默病，老年痴呆等。
-
公开(公告)号：US5354766A
公开(公告)日：1994-10-11
申请号：US080259
申请日：1993-06-23
Applicant: Takehiko Naka , Yoshiyuki Inada
Inventor： Takehiko Naka , Yoshiyuki Inada
IPC: A61K31/415 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/433 , A61K31/435 , A61K31/4365 , A61K31/495 , A61K31/505 , A61K31/513 , A61K31/517 , A61K31/535 , A61P9/00 , A61P9/10 , A61P9/12 , A61P25/28 , A61P43/00 , B29D22/00 , B32B27/42 , C07D285/08 , C07D403/10 , C07D413/10 , C07D417/10 , C07D419/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00 , C07D271/07
CPC classification number: C07D403/10 , A61K31/42 , A61K31/435 , C07D411/10 , C07D411/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D419/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04 , Y02P20/55
Abstract: ##STR1## Compounds shown by the above formula or salt thereof show a strong angiotensin II antagonistic activity and hypotensive action and CNS activity, and are useful as therapeutic agents of circulatory diseases such as hypertensive diseases and heart diseases (e.g. hypercardia, heart failure, cardiac infarction), strokes, cerebral apoplexy, nephritis, atherosclerosis, Alzheimer's disease, senile dementia, etc.
Abstract translation: 上述式表示的化合物或其盐显示出强的血管紧张素II拮抗作用和降血压作用和CNS活性，并且可用作循环系统疾病如高血压性疾病和心脏病（例如高血压，心力衰竭，心脏病 梗塞），中风，脑中风，肾炎，动脉粥样硬化，阿尔茨海默病，老年痴呆等。
-
公开(公告)号：US4675044A
公开(公告)日：1987-06-23
申请号：US794197
申请日：1985-11-01
Applicant: Walter G. Brouwer , Allyn R. Bell , Allen R. Blem , Robert A. Davis
Inventor： Walter G. Brouwer , Allyn R. Bell , Allen R. Blem , Robert A. Davis
IPC: A01N43/88 , C07C327/58 , C07D291/06 , C07D419/04 , C07D419/10
CPC classification number: C07D419/04 , A01N43/88 , C07C327/58 , C07D291/06 , C07D419/10
Abstract: Disclosed are derivatives of 3-aryl-5,6-dihydro-1,4,2-oxathiazines and their oxides for use as herbicides, fungicides, plant dessicants and defoliants in agricultural and biocidal applications. Also disclosed are methods of making these compounds.
Abstract translation: 公开了3-芳基-5,6-二氢-1,4,2-氧噻嗪及其氧化物的衍生物，其用作农业和杀生物应用中的除草剂，杀真菌剂，植物干燥剂和脱叶剂。 还公开了制备这些化合物的方法。
-
公开(公告)号：US20240109884A1
公开(公告)日：2024-04-04
申请号：US18267913
申请日：2022-03-30
Applicant: LG CHEM, LTD.
Inventor： Minjun KIM , Dong Hoon LEE , Donghee KIM , Jongsoo SONG , Sungju PARK
IPC: C07D419/14 , C07D417/10 , C07D417/14 , C07D419/10 , H10K85/60
CPC classification number: C07D419/14 , C07D417/10 , C07D417/14 , C07D419/10 , H10K85/615 , H10K85/633 , H10K85/654 , H10K85/6574 , H10K85/6576
Abstract: Provided is a compound of Chemical Formula 1:
wherein: A1 represents Chemical Formula 1-a:
where X is O or S; and Ar1 is a substituted or unsubstituted C6-60 aryl or C2-60 heteroaryl containing at least one of N, O and S; and A2 is Chemical Formula 1-b or Chemical Formula 1-c:
wherein: L1 to L4 are each independently a single bond, a substituted or unsubstituted C6-60 arylene, or a substituted or unsubstituted C2-60 heteroarylene containing at least one of N, O and S; Ar2 to Ar5 are each independently a substituted or unsubstituted C6-60 aryl or C2-60 heteroaryl containing at least one of N, O and S; D is deuterium; and n is an integer of 0 to 5, and an organic light emitting device including the same. An organic light-emitting device containing the compound exhibits improved efficiency, driving voltage and/or lifespan characteristics.
-
公开(公告)号：US11950502B2
公开(公告)日：2024-04-02
申请号：US17233438
申请日：2021-04-17
Applicant: DUK SAN NEOLUX CO., LTD.
Inventor： Hyoung Keun Park , Yun Suk Lee , Ki Ho So , Jong Gwang Park , Yeon Seok Jeong , Jung Hwan Park , Sun Hee Lee , Hak Young Lee
IPC: H01L51/00 , C07D209/82 , C07D209/88 , C07D333/76 , C09K11/06 , H01L51/50 , H10K50/00 , H10K50/15 , H10K50/16 , H10K50/17 , H10K85/60 , H10K99/00 , C07D419/10 , C07D419/12 , C07D419/14 , H10K10/46 , H10K30/00
CPC classification number: H10K85/649 , C07D209/82 , C07D209/88 , C07D333/76 , C09K11/06 , H10K50/00 , H10K50/15 , H10K50/16 , H10K50/17 , H10K99/00 , C07D419/10 , C07D419/12 , C07D419/14 , H10K10/462 , H10K30/00
Abstract: Provided is a novel compound capable of improving the luminous efficiency, stability and life span of a device, an organic electric element using the same, and an electronic device thereof.
